B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GRIN2A

MOLECULAR TARGET

glutamate ionotropic receptor NMDA type subunit 2A

UniProt: Q12879NCBI Gene: 290317 compounds

GRIN2A (glutamate ionotropic receptor NMDA type subunit 2A) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GRIN2A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Glutamic Acid3.3026
2Glutamic Acid3.3026
3Glycine2.4010
4pentamidine1.956
5Dextromethorphan Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of1.614
6Levorphanol1.614
7Aspartic Acid1.393
8cycloserine1.393
9D-Aspartic Acid1.102
10Dextrorphan Dextro form of levorphanol. It acts as1.102
11Ethidium1.102
12Memantine AMANTADINE derivative that has some dopaminergic effects. It has been proposed as1.102
13Dextrothyroxine0.691
14Dizocilpine Maleate0.691
15Ibogaine0.691
16Ibotenic Acid0.691
17Spermine0.691

About GRIN2A as a Drug Target

GRIN2A (glutamate ionotropic receptor NMDA type subunit 2A) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented GRIN2A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GRIN2A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.